HUI Y ZHANG
Nail Technician in Philadelphia, PA
License number
Pennsylvania 010014
Category
Cosmetology
Type
Nail Technician Temp Auth to Practice
Address
Address
Philadelphia, PA 19148
Personal information
See more information about HUI Y ZHANG at radaris.comName
Address
Phone
305 Cornwall Dr, Pittsburgh, PA 15238
Professional information
Immunobioanalysis At Qps
Position:
Director of Immunobioanalysis at QPS, LLC
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
QPS, LLC
since Feb 2002
-
Director of Immunobioanalysis
DuPont Pharmaceuticals
2001 - 2001
-
Consultant
Cornnel Univ. Med. Coll. Burke Research Institute
1992 - 2001
-
Technologist
Mount Sinai Medical Center
1990 - 1992
-
Research Associate
Institute of Materia Medica
1986 - 1990
-
Research associate
Education:
Sichuan University 1980 - 1986
M.B., Medicine
M.B., Medicine
Honor & Awards:
2005 QPS Founder's award
Consultant At Bcg
Position:
Consultant at BCG
Location:
Greater Philadelphia Area
Industry:
Management Consulting
Work:
BCG
-
Consultant
Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target
US Patent:
6653443, Nov 25, 2003
Filed:
Apr 8, 2002
Appl. No.:
10/118575
Inventors:
Hui Zhang - Philadelphia PA
Roger J. Pomerantz - Chalfont PA
Bin Yang - Bala Cynwyd PA
Roger J. Pomerantz - Chalfont PA
Bin Yang - Bala Cynwyd PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3804
US Classification:
530327, 530324, 530325, 530326, 530826
Abstract:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif, by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target
US Patent:
7226741, Jun 5, 2007
Filed:
Oct 17, 2003
Appl. No.:
10/688100
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911, 435 9133
Abstract:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
Method For Increasing Transduction Efficiency Of Recombinant Retroviral Vectors
US Patent:
5763242, Jun 9, 1998
Filed:
Feb 8, 1995
Appl. No.:
8/385446
Inventors:
Hui Zhang - Philadelphia PA
Roger J. Pomerantz - Chalfont PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12N 1500, C12N 1586, C12N 510
US Classification:
4351723
Abstract:
A method for improving the transduction efficiency of retroviral vectors into a host cell wherein the retroviral vectors are incubated with deoxyribonucleoside triphosphates prior to transduction into the host cell is provided.
Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target
US Patent:
7498138, Mar 3, 2009
Filed:
Jun 4, 2007
Appl. No.:
11/809953
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911
Abstract:
The HIV-1 protein Vif comprises a multimerization domain that allows Vif-Vif interaction and Vif multimerization, which is important for Vif function in the HIV-1 life-cycle. A method for screening for an antagonist of Vif comprises contacting the multimerization domain of Vif with a test compound that specifically binds the multimerization domain. Antagonists identified by the screening assay inhibit Vif multimerization. The antagonists inhibit essential functions of Vif and accordingly are useful as inhibitors of HIV-1 replication.